Do mutations of the Pendred syndrome gene, SLC26A4, confer resistance to asthma and hypertension?

National Institutes of Health, 5 Research Court, Rockville, Maryland 20850-3320, USA.
Journal of Medical Genetics (Impact Factor: 5.64). 04/2009; 46(6):405-6. DOI: 10.1136/jmg.2008.063610
Source: PubMed

ABSTRACT Mutations of SLC26A4 cause Pendred syndrome, an autosomal recessive disorder comprising goitre and deafness with enlarged vestibular aqueducts (EVA). Recent studies in mouse models implicate Slc26a4 in the pathogenesis of asthma and hypertension. We hypothesise that asthma and hypertension are less prevalent among humans with SLC26A4 mutations.
We reviewed medical histories and SLC26A4 genotypes for 80 individuals with EVA and 130 of their unaffected family members enrolled in a study of EVA. We used Fisher's exact test to compare the prevalence of asthma and hypertension among groups of subjects with zero, one, or two mutant alleles of SLC26A4.
Although none of the 21 subjects with two mutant alleles of SLC26A4 had asthma or hypertension, there were no statistically significant differences in the prevalence of asthma or hypertension among subjects with zero, one, or two mutant alleles.
There might be a protective effect of SLC26A4 mutations for asthma and hypertension but our study is statistically underpowered to detect this effect. Study sizes of at least 1125 and 504 individuals will be needed for 80% power to detect an effect at alpha = 0.05 for asthma and hypertension, respectively. Our hypothesis merits a larger study since it has implications for potential strategies to treat hearing loss by manipulating SLC26A4 expression or function.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal intercalated cells mediate secretion or absorption of Cl- and OH(-)/H(+) equivalents in the connecting segment (CNT) and cortical collecting duct (CCD). In so doing, they regulate acid-base balance, vascular volume and blood pressure. Cl(-) absorption is either electrogenic and amiloride-sensitive, or electroneutral and thiazide-sensitive. However, which Cl(-) transporter(s) are targeted by these diuretics is debated. While ENaC does not transport Cl(-), it modulates Cl(-) transport probably by generating a lumen-negative voltage, which drives Cl(-) flux across tight junctions. In addition, recent evidence indicates that ENaC inhibition increases electrogenic Cl- secretion via a type A intercalated cell. During ENaC blockade, Cl(-) is taken up across the basolateral membrane through the Na(+)-K(+)-2Cl(-) cotransporter (NKCC1) and then secreted across the apical membrane through a conductive pathway (a Cl(-) channel or an electrogenic exchanger). the mechanism of this apical Cl(-) secretion is unresolved. In contrast, thiazide diuretics inhibit electroneutral Cl(-) absorption mediated by a Na(+)-dependent Cl(-)/HCO3(-) exchanger. The relative contribution of the thiazide and the amiloride-sensitive components of Cl(-) absorption varies between studies and probably depends on the treatment model employed. Cl(-) absorption increases markedly with angiotensin and aldosterone administration, largely by up-regulating the Na(+)-independent Cl(-)/HCO3(-) exchanger, pendrin. In the absence of pendrin (Slc26a4 (-/-) or pendrin null mice), aldosterone-stimulated Cl(-) absorption is significantly reduced, which attenuates the pressor response to this steroid hormone. Pendrin also modulates aldosterone-induced changes in ENaC abundance and function through a kidney-specific mechanism that does not involve changes in the concentration of a circulating hormone. Instead, pendrin changes ENaC abundance and function, at least in part, by altering luminal HCO3(-). This review summarizes mechanisms of Cl(-) transport in CNT and CCD, and how these transporters contribute to the regulation of extracellular volume and blood pressure.
    AJP Renal Physiology 05/2013; 305(4). DOI:10.1152/ajprenal.00022.2013 · 4.42 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This film presents the content of a peer-reviewed written English public health journal article. The article topic is health inequities experienced by deaf sign language users. The article describes four issues that underlie health inequities experienced by deaf sign language users and proposes six public health approaches to address these health and healthcare inequities. The film conveys in American Sign Language (ASL) the main learning points of the article. In addition to language translation (from English to ASL), the film team, comprised of deaf and hearing members, made the article content accessible by presenting the information in a culturally appropriate way, with dialog between deaf characters in the context of a story that feels relevant to the viewer. This approach can be used to reach deaf audiences with other health education and public health messages. A similar approach can be used with other populations. The film is captioned in English and includes an English voice track.
    140st APHA Annual Meeting and Exposition 2012; 10/2012
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Deaf American Sign Language (ASL) users represent a small population at risk for marginalization from research and surveillance activities resulting from cultural, language, and ethical challenges. The Deaf community's view of deafness as a cultural identity, rather than a disability, contradicts the medical community's perception of deafness as a disease or deficiency in need of correction or elimination. These differences continue to have significant cultural and social implications within the Deaf community, resulting in mistrust of research opportunities. Two particularly contentious ethical topics for the Deaf community are the absence of community representation in genetic research and the lack of accessible informed consents and research materials. This article outlines a series of innovative strategies and solutions to these issues, including the importance of community representation and collaboration with researchers studying deaf populations. (Am J Public Health. Published online ahead of print October 17, 2013: e1-e6. doi:10.2105/AJPH.2013.301343).
    American Journal of Public Health 10/2013; 103(12). DOI:10.2105/AJPH.2013.301343 · 4.23 Impact Factor


Available from